CTIS2024-513431-25-00
Recruiting
Phase 1
Phase I / II Clinical Trial, multicenter, open, of infusion of activated NK cells for the treatment of children, adolescents and young adults with sarcomas.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Sarcomas
- Sponsor
- Hospital Universitario La Paz
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients aged 0\-40 years diagnosed with malignant sarcoma, who at the end of conventional treatment still have detectable residual disease (based on imaging techniques) or in case of stable disease or minimal disease when there is an absence of clinical benefit from chemotherapy (poor tolerance due to adverse effects related to chemotherapy)., Lansky/Karnofsky index \> 60%., Mild\-moderate (\<4\) organ functional impairment (hepatic, renal, respiratory), according to National Cancer Institute criteria (NCI CTCAE v5\.0\)., Left ventricular ejection fraction \>39%., Adult subjects who had voluntarily signed the informed consent prior to the first intervention of the study., Minor subjects whose representative/legal guardian voluntarily signed the informed consent prior to the first intervention of the study., In the case of mature minors (12 \- 17 years of age), in addition to the consent signed by the legal guardian, the minor's assent will be obtained., Women of childbearing capacity must have a negative pregnancy test at inclusion and must agree to use highly effective contraceptive methods (diaphragms plus spermicide or male condom plus spermicide, oral contraceptive combined with a second method of contraceptive implant, injectable contraceptive, permanent intrauterine device, sexual abstinence or vasectomized partner) during their participation in the study and within 30 days of the last visit., Presence of a compatible haploidentical donor (parent or sibling).
Exclusion Criteria
- •Patients with a history of poor therapeutic compliance., Patients who after a psycho\-social evaluation are censored as unsuitable for the procedure. ? Socio\-familial situation that makes proper participation in the study impossible. ? Patients with emotional or psychological problems secondary to the disease, such as post\-traumatic stress disorder, phobias, delirium, psychosis, requiring specialist support. ? Evaluation of the involvement of family members in the patient's health. ? Impossibility to understand information about the trial., Severe functional organ impairment (hepatic, renal, respiratory) (4\), according to the criteria of the National Cancer Institute (NCI CTCAE 5\.0\)., The contraindications, interactions, precautions for use and dose reductions indicated in the corresponding data sheets should be considered., Subjects who have been administered other investigational drugs in the 90 days prior to inclusion.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Infusion of activated NK cells for the treatment of children, adolescents and young adults with sarcomas.EUCTR2016-003578-42-ESAntonio Pérez-Martínez10
Active, not recruiting
Not Applicable
Trial that evaluates the combination treatment of Trabectedin and Radiotherapy in Soft Tissue Sarcoma patients.Soft Tissue SarcomaTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-001549-26-ESGEIS96
Active, not recruiting
Phase 1
Clinical trial phase I/II multicentric, open, randomized and controlled for the study of stem cells as therapy critical ischemia in low limbs in insulinized type 2 diabetic patients: study of the insuliEUCTR2010-019774-33-ESFundación progreso y Salud48
Unknown
Phase 1
Phase I/II Multicenter, Open-label Trial to Evaluate the Safety and Pharmacokinetics of Alpha-1 MP in Patients with Alpha1-Antitrypsin DeficiencyAlpha1-antitrypsin deficiencyJPRN-jRCT2080223105Grifols Japan K.K.3
Not yet recruiting
Not Applicable
Phase I / II, Multicenter Clinical trial to evaluate the safe dose range and confirm the effectiveness and safety of the maximum tolerated dose of Docetaxel In combination with SH003 in patients with solid tumor who are indicated for DocetaxelKCT0004770Korea University Anam Hospital110